Revenue at June 30, 2016: €376.7 million, up 65.7%
Change in pro forma revenue* at constant exchange rates: - 2.3%
Guerbet is reporting revenue of €376.7 million for the 1st half of 2016, up 65.7% from 2015. At constant exchange rates, the Group posted sales of €388.6 million, slightly down 2.3% from the pro forma revenue for the first half of 2015.
- good Dotarem sales in both Europe and the US resulted in half-year revenue of €121.8 million for MRI, up 5.5%
- the X-ray segment fell by 6.8% to €205.3 million, mainly due to Optiray, but its decline began to slow down in the second quarter thanks to stimulus actions undertaken since the acquisition of CMDS
- the performance of Lipiodol® and Patent Blue V increased the IRT segment’s revenue by 18.3% to €25.4 million
- lastly, the Imaging Solutions and Services (ISS) segment is down nearly 7.4% with revenue of €34.5 million, reflecting lower injector sales.
The Group confirms its annual targets and its ability to start growing again in 2017.